Literature DB >> 3537887

HLA-A,B and DR matching in corneal transplantation.

H M Boisjoly, R Roy, I Dubé, P A Laughrea, R Michaud, P Douville, J Heébert.   

Abstract

One hundred eighty-five consecutive corneal transplants were performed in recipients selected on the basis of the best available HLA-A,B and DR match. Endothelial rejection-free transplant survival in this group was compared to a retrospective historical control group of 199 consecutive transplants performed in recipients selected on the basis of age and longest wait criteria. The two groups were comparable with regards to primary diagnosis, preoperative corneal vascularization, donor and recipient age, and operative techniques. Thirty-eight transplants in the study group and 28 transplants in the control group were at high risk for endothelial transplant rejection. At 12 months, the estimated rejection-free survival (Kaplan-Meier method) of the high-risk study group transplants was 87% compared to 74% for the high-risk historical control group and transplants. This difference did not reach the significant level of 0.05 with the log-rank test. The 12-month estimated rejection-free survival of low-risk study group and historical control group transplants were similar. In the study group, the 12-month estimated rejection-free survival of well-matched transplants was 95% compared to 83% for poorly matched transplants (log rank, P less than 0.02). These findings suggest that a relationship exists between HLA-A,B and DR compatibility of donor and recipient and the corneal rejection-free transplant survival.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3537887     DOI: 10.1016/s0161-6420(86)33578-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

Review 1.  Immunology of corneal transplantation.

Authors:  W H Constad; K Taraschanskiy
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

Review 2.  [Typing for HLA matching. Advantages for keratoplasty].

Authors:  R Ignatius; F Hoffmann
Journal:  Ophthalmologe       Date:  2007-03       Impact factor: 1.059

3.  Cross-matches on donor cadaver retinal pigment epithelial cells in corneal risk patients.

Authors:  N Zavazava; B Nölle; G Duncker; S Jenisch; E Westphal; V Eckstein; W Müller-Ruchholtz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-03       Impact factor: 3.117

4.  DNA-based HLA class II postmortem typing: evaluation of different techniques for prospective corneal allografting.

Authors:  S Jenisch; E Westphal; N Zavazava; C Dürr; G Duncker; B Nölle; W Müller-Ruchholtz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-10       Impact factor: 3.117

5.  Effect of ABO blood group mismatching on corneal epithelial cells: an in vitro study.

Authors:  J H Chan; H S Dua; A Powell-Richards; D R Jones; I M Harris
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

6.  Tacrolimus immunosuppression in high-risk corneal grafts.

Authors:  A Joseph; D Raj; V Shanmuganathan; R J Powell; H S Dua
Journal:  Br J Ophthalmol       Date:  2006-09-06       Impact factor: 4.638

7.  Orthotopic corneal transplantation in the mouse--a new surgical technique with minimal endothelial cell loss.

Authors:  E P Zhang; S Schründer; F Hoffmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-11       Impact factor: 3.117

8.  Clinical and immunohistochemical correlation of herpetic keratitis with the expression of HLA-DR antigen.

Authors:  S Tang; O F Scheiffarth; F H Stefani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-03       Impact factor: 3.117

9.  HLA-A, HLA-B and HLA-DR matching reduces the rate of corneal allograft rejection.

Authors:  Riad Khaireddin; Joachim Wachtlin; Werner Hopfenmüller; Friedrich Hoffmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-08-29       Impact factor: 3.117

10.  HLA typing from human donor eyes.

Authors:  I Baumgartner; V Huber-Spitzy; G Grabner; W R Mayr
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.